Long-term (5 years) evaluation of tofersen in SOD1-ALS: final results from the integrated analysis of Study 101 Parts A/B, a Phase 1/2 ascending dose trial, and the open-label extension (NEALS 2026) - Oct 23, 2026 - Abstract #197; Pres time: Oct 29, 2026; 04:50 PM - 06:30 PM; Location: (Opal Sands) Ballroom; No abstract available
Clinical • P1/2 data
|